What is the difference between cyclical and continuous HRT?
To understand bleeding on continuous HRT, it helps to first understand the structural difference between the two main types of combined HRT regimens.
Cyclical (sequential) HRT uses estrogen throughout the cycle, with progestogen added for a set number of days per month. This pattern deliberately mimics the hormonal cycle and produces a predictable withdrawal bleed when progestogen is withdrawn — similar in timing to a period. Women who are still peri-menopausal or who want predictable bleeding often start here.
Continuous combined HRT provides both estrogen and progestogen every day without a break. The goal is to suppress endometrial proliferation entirely over time, eventually producing amenorrhea (no monthly bleeding). This is typically recommended for women at least 12 months post-menopause.
The first few months of continuous combined HRT are the transition period where bleeding is most likely — the endometrium is adjusting from a cyclic pattern to a stable, atrophic state.
Why does breakthrough bleeding happen on continuous HRT?
Several mechanisms can produce bleeding during continuous HRT:
Endometrial instability during transition
The endometrium (uterine lining) does not immediately stabilize on continuous progestogen. At the start of a continuous combined regimen, the lining may still have areas of residual proliferative activity from prior cyclic stimulation. As progestogen consistently suppresses estrogen’s proliferative effect, the lining sheds unevenly and irregularly before becoming atrophic. This irregular shedding is the most common cause of early breakthrough bleeding.
For most women, this transitional bleeding resolves within 3–6 months as the endometrium fully transitions to the atrophic state.
Estrogen-progestogen dose imbalance
Continuous combined HRT requires a balance between estrogen (which stimulates endometrial growth) and progestogen (which suppresses it). If estrogen levels are relatively high compared to the progestogen dose — either because of the formulation chosen, individual absorption differences, or adherence patterns — breakthrough endometrial activity can occur.
Dose recalibration by a clinician is often the solution when bleeding persists beyond the expected early window. Delivery route can also matter: transdermal estrogen (patches, gels, sprays) produces more stable serum levels than oral estrogen and may be associated with fewer bleeding irregularities in some women.
Missed or inconsistent dosing
Continuous HRT depends on consistent daily intake. Missing doses — even occasionally — can create fluctuations in progestogen coverage that allow transient endometrial activity. If bleeding correlates with inconsistent dosing, improving adherence often resolves it.
Submucosal fibroids or polyps
Structural uterine pathology — particularly submucosal fibroids (fibroids located inside the uterine cavity) or endometrial polyps — can cause bleeding independent of HRT. These conditions may be pre-existing and only become symptomatic once hormone levels shift. Persistent or heavy bleeding that does not follow the expected transition pattern warrants imaging to rule out structural pathology.
Spotting in the first three to six months of continuous combined HRT is the endometrium settling into suppression — not a warning sign.
How long does bleeding last on continuous HRT, and when should you be concerned?
Clinical guidelines generally characterize the following patterns:
- First 3–6 months: Irregular spotting or light breakthrough bleeding is common and expected as part of the endometrial transition. Most women see improvement progressively through this window.
- Months 6–12: Bleeding should be diminishing significantly or absent. Persistent bleeding in this window should prompt a clinical review to assess dose adequacy and rule out underlying pathology.
- After 12 months of amenorrhea: Any new bleeding requires evaluation. Postmenopausal bleeding — defined as bleeding after 12 months without a period — is a symptom that warrants clinical workup to exclude endometrial pathology, including endometrial hyperplasia or cancer.
The pattern that should always trigger a clinician call, regardless of timing:
- Heavy bleeding (saturating a pad or tampon in an hour for multiple hours)
- Bleeding with pelvic pain
- New bleeding after a period of established amenorrhea on continuous HRT
- Bleeding that increases in frequency or volume over time rather than diminishing
What will a clinician evaluate for persistent bleeding?
If you report persistent or concerning bleeding on continuous HRT, a clinician will generally want to assess:
- Current regimen details: Estrogen type, dose, and delivery route. Progestogen type, dose, and daily consistency. Duration of continuous combined therapy.
- Bleeding pattern: Onset timing relative to starting continuous HRT, volume, frequency, any associated symptoms.
- Endometrial assessment: Transvaginal ultrasound is typically used to measure endometrial thickness. An endometrial biopsy may be recommended if imaging suggests thickening or if bleeding is persistent and unexplained.
- Structural pathology: Ultrasound can also identify fibroids and polyps that might be contributing to bleeding.
Progestogen type and bleeding patterns
The type of progestogen in a continuous combined regimen can influence bleeding patterns. Micronized progesterone (bioidentical progesterone) has a somewhat different endometrial effect profile than synthetic progestins (medroxyprogesterone acetate, norethisterone, dydrogesterone, and others). Some women with persistent breakthrough bleeding on one progestogen type see improvement on another.
Delivery route matters as well. The Mirena intrauterine system, which delivers levonorgestrel locally to the uterus, is sometimes used in perimenopausal women as the progestogen component of HRT — with the advantage of very localized endometrial suppression and often favorable bleeding profiles after an initial adjustment period.
These decisions require individual clinical assessment. If your current regimen is producing persistent irregular bleeding that concerns you, a clinician review of progestogen type and delivery is a reasonable next step.
Frequently asked questions
What causes bleeding on continuous HRT?
Breakthrough bleeding on continuous combined HRT is most often caused by irregular endometrial shedding as the uterine lining transitions from a cyclic to an atrophic state. The endometrium takes weeks to months to fully stabilize on continuous progestogen. Dose imbalances between estrogen and progestogen are another common cause.
How long does breakthrough bleeding last on continuous HRT?
For most women, irregular spotting or light bleeding resolves within the first 3–6 months of continuous combined HRT as the endometrium becomes atrophic. Persistent or heavy bleeding beyond 6 months warrants clinical evaluation.
Is bleeding on continuous HRT always normal?
Light spotting in the first few months is common and usually reflects endometrial adjustment. Any heavy bleeding, bleeding that starts after a prolonged amenorrhea period on continuous HRT, or bleeding that does not follow the expected early-resolution pattern should be evaluated by a clinician to rule out endometrial pathology.
Does bleeding on continuous HRT mean my dose needs adjusting?
Sometimes. Persistent bleeding can signal that the ratio of estrogen to progestogen needs recalibration. A clinician may also assess whether switching formulation, delivery route, or progestogen type could reduce irregular bleeding. Do not adjust your own dose without clinician guidance.
When should I see a doctor about bleeding on HRT?
Contact your clinician if bleeding is heavy (heavier than a normal period), if you develop bleeding after 12 months of amenorrhea on continuous HRT, if you experience pain along with bleeding, or if bleeding appears at an unexpected time and does not resolve within a few weeks.
Can I switch from cyclical to continuous HRT to avoid periods?
Yes, continuous combined HRT is specifically designed to minimize or eliminate withdrawal bleeding. Many women transition to it after at least a year post-menopause. The transition involves a period of irregular spotting before the endometrium stabilizes. Your clinician can advise on timing and the right formulation for your history.